Amneal Pharmaceuticals, Inc.

DB:2DT Stock Report

Market Cap: €2.4b

Amneal Pharmaceuticals Management

Management criteria checks 4/4

We currently do not have sufficient information about the CEO.

Key information

Chirag Patel

Chief executive officer

US$2.4m

Total compensation

CEO salary percentage31.6%
CEO tenure20yrs
CEO ownership7.0%
Management average tenure5.5yrs
Board average tenure6.7yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Chirag Patel's remuneration changed compared to Amneal Pharmaceuticals's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$184m

Jun 30 2024n/an/a

-US$175m

Mar 31 2024n/an/a

-US$169m

Dec 31 2023US$2mUS$750k

-US$84m

Sep 30 2023n/an/a

US$10m

Jun 30 2023n/an/a

-US$2m

Mar 31 2023n/an/a

-US$135m

Dec 31 2022US$5mUS$750k

-US$130m

Sep 30 2022n/an/a

-US$132m

Jun 30 2022n/an/a

-US$134m

Mar 31 2022n/an/a

US$2m

Dec 31 2021US$5mUS$724k

US$11m

Sep 30 2021n/an/a

US$14m

Jun 30 2021n/an/a

US$9m

Mar 31 2021n/an/a

-US$17m

Dec 31 2020US$2mUS$1

US$91m

Sep 30 2020n/an/a

US$62m

Jun 30 2020n/an/a

-US$194m

Mar 31 2020n/an/a

-US$199m

Dec 31 2019US$446kUS$44k

-US$362m

Sep 30 2019n/an/a

-US$339m

Jun 30 2019n/an/a

-US$67m

Mar 31 2019n/an/a

-US$69m

Dec 31 2018US$325kn/a

-US$21m

Compensation vs Market: Chirag's total compensation ($USD2.37M) is about average for companies of similar size in the German market ($USD2.26M).

Compensation vs Earnings: Chirag's compensation has been consistent with company performance over the past year.

CEO

Chirag Patel (57 yo)

20yrs

Tenure

US$2,370,385

Compensation

Mr. Chirag K. Patel has been Co-Chief Executive Officer, President and Director of Amneal Pharmaceuticals, Inc. since August 3, 2019. Mr. Patel Co-founded Amneal Pharmaceuticals LLC in 2005 and serves as D...

Leadership Team

NamePositionTenureCompensationOwnership
Chirag Patel
Co-Founder20yrsUS$2.37m7.03%
€ 165.9m
Chintu Patel
Co-Founder23yrsUS$2.37m8.15%
€ 192.5m
Anastasios Konidaris
Executive VP & CFO4.8yrsUS$1.89m0.17%
€ 4.0m
Jason Daly
Senior VP3yrsUS$1.35m0%
€ 0
Nikita Shah
Executive VP & Chief Human Resources Officer11yrsUS$1.53m0.094%
€ 2.2m
Andrew Boyer
Executive VP & Chief Commercial Officer of Generics6.9yrsUS$1.94m0.083%
€ 2.0m
Anthony DiMeo
Head of Investor Relationsno datano datano data
Gregory Sgammato
Senior Vice President of Corporate Development2yrsno datano data
Pranav Mehta
Senior VP of Strategic Sourcing & Supply Management2yrsno datano data
Sanjay Jain
Chief Quality Officer6yrsno datano data
Srinivas Kone
Senior VP & Chief Scientific Officer of Generics5yrsno datano data
Stanley Fisher
Vice President & Head of Medical Affairsno datano datano data

5.5yrs

Average Tenure

54.5yo

Average Age

Experienced Management: 2DT's management team is seasoned and experienced (5.5 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Chirag Patel
Co-Founder20yrsUS$2.37m7.03%
€ 165.9m
Chintu Patel
Co-Founder23yrsUS$2.37m8.15%
€ 192.5m
Paul Meister
Independent Chairman of the Board5.4yrsUS$299.08k0.23%
€ 5.5m
J. Buchi
Independent Director6.7yrsUS$302.20k0.085%
€ 2.0m
Ted Nark
Independent Director6.7yrsUS$244.70k0.097%
€ 2.3m
Shlomo Yanai
Independent Director5.1yrsUS$254.70k0.079%
€ 1.9m
Jeffrey George
Independent Director5.1yrsUS$277.20k0.087%
€ 2.1m
Gautam Patel
Director6.7yrsUS$217.20k0.64%
€ 15.0m
Deborah Autor
Independent Director2.5yrsUS$267.04k0.017%
€ 407.0k
Emily Alva
Independent Director6.7yrsUS$217.20k0.081%
€ 1.9m
John Kiely
Independent Director5.1yrsUS$284.70k0.086%
€ 2.0m

6.7yrs

Average Tenure

57yo

Average Age

Experienced Board: 2DT's board of directors are considered experienced (6.7 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/15 10:04
End of Day Share Price 2025/01/14 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Amneal Pharmaceuticals, Inc. is covered by 20 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Balaji PrasadBarclays
Balaji PrasadBarclays
Gary NachmanBMO Capital Markets Equity Research